Are you Dr. Irizarry?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
15 Parkman St
Wac 830
Boston, MA 02114Phone+1 617-726-1728Fax+1 617-726-4101
Summary
- Dr. Michael Irizarry, MD is a board certified neurologist in Boston, Massachusetts. He is currently licensed to practice medicine in North Carolina. He is a VP Early Clinical Development at Ltd..
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
Massachusetts General HospitalInternship, Internal Medicine, 1990 - 1991
Georgetown University School of MedicineClass of 1990
Certifications & Licensure
NC State Medical License 2006 - 2025- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 52 citationsCaffeine protects against combined paraquat and maneb-induced dopaminergic neuron degenerationAnil Kachroo, Michael C. Irizarry, Michael A. Schwarzschild
Experimental Neurology. 2010-06-01 - 44 citationsClinical and neuropathological correlates of dementia with Lewy bodies.E. Gómez-Tortosa, Michael C. Irizarry, Teresa Gomez-Isla, B. T. Hyman
Annals of the New York Academy of Sciences. 2006-01-25 - 517 citationsVenezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onsetNancy S. Wexler, Judith Lorimer, Julie Porter, Fidela Gomez, Carol Moskowitz
Proceedings of the National Academy of Sciences of the United States of America. 2004-03-09
Press Mentions
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the ad/pd™ 2023 Annual MeetingMarch 22nd, 2023- FDA Approves, Leqembi, New Treatment for Early Alzheimer’sJanuary 6th, 2023
- Michael Irizarry, S.VP, Clinical Research,Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAICDecember 14th, 2022
- Join now to see all
Grant Support
- Transgenic Models Of Alzheimers DiseaseNational Institute On Aging1997–2001
